Toxoplasmosis Treatment in HIV/AIDS: Standard Regimen and Supportive Care

Toxoplasmic encephalitis (TE) in HIV/AIDS (CD4 <100) requires prompt, coordinated therapy.

First-Line Therapy (Acute Treatment, ≥6 weeks)

  • Pyrimethamine 200 mg loading dose, then 50–75 mg/day (adjust for weight).
  • Sulfadiazine 1–1.5 g QID (total 4–6 g/day).
  • Leucovorin (folinic acid) 10–25 mg/day with each pyrimethamine dose—prevents bone marrow suppression.

Alternative if sulfa-allergic: Pyrimethamine + clindamycin 600 mg IV/PO QID ± leucovorin.

Adjunctive Therapy for Severe TE

  • Corticosteroids (dexamethasone 4 mg Q6H) for mass effect/edema—taper as imaging improves.
  • Anticonvulsants for seizure prophylaxis/treatment (levetiracetam preferred).

Maintenance Therapy (Secondary Prophylaxis)

Continue pyrimethamine 25–50 mg + sulfadiazine 2–4 g + leucovorin daily until CD4 >200 for ≥6 months on ART.

Supportive Care

  • ART initiation (if not on it)—ideally within 2 weeks of TE treatment (IRIS risk).
  • Monitor CBC weekly × 2, then biweekly (neutropenia, thrombocytopenia).
  • Hydration, nutrition, electrolytes.
  • Serial imaging (MRI/CT) to assess response.

Primary Prophylaxis

TMP-SMX (Bactrim DS daily) if CD4 <100—also prevents PCP. Alternatives: dapsone, atovaquone.

Multidisciplinary care (ID, neurology, HIV) optimizes outcomes.

HIV & AIDS - Related Articles